Palantir (PLTR 0.39%) has been on fire over the past years, but volatility has been prevalent. The data analytics and artificial intelligence (AI) specialist has generated stock price gains of 1,730% over the past three years, but has fallen by at least 20% at least 10 times. There's more. During the two years between early 2021 and early 2023, Palantir stock plummeted more than 80% -- so it isn't...
Palantir (PLTR 0.39%) has been on fire over the past years, but volatility has been prevalent. The data analytics and artificial intelligence (AI) specialist has generated stock price gains of 1,730% over the past three years, but has fallen by at least 20% at least 10 times. There's more. During the two years between early 2021 and early 2023, Palantir stock plummeted more than 80% -- so it isn't for the squeamish. The stock currently trades for an eye-popping 241 times earnings and 115 times forward earnings (as of this writing), yet one Wall Street analyst calls Palantir "extraordinary." Citi says Palantir stock is a buy Citi analyst Tyler Radke recently made a splash, maintaining a buy rating and raising his price target on Palantir stock to a Street-high $260. For those keeping score at home, this represents potential gains for investors of 70% compared to Thursday's closing price. The analyst cites Palantir's strong results and relentless growth as the basis for his bullish stance. Radke points out that "These revisions mark some of the strongest at scale we've seen in enterprise software." He goes on to say that "Palantir's momentum increasingly stands out in a software market where accelerating growth stories are rare." I think the analyst hit the nail on the head. In the fourth quarter, Palantir's revenue grew 70% year over year, but this belies the underlying strength of the business. The U.S. commercial segment -- which includes the company's Artificial Intelligence Platform (AIP) -- surged 137% year over year and 28% sequentially, representing 36% of Palantir's total revenue. AIP is attracting not only enterprise customers but also government agencies. Equally as impressive is the company's remaining performance obligation (RPO) -- contractually obligated sales not yet included in revenue -- which surged 143% to $4.2 billion, adding $1.6 billion in the fourth quarter alone. This gives the company a solid foundation for future growth. Expand NASDAQ : PLTR...
Key Points Palantir stock has gained 1,720% over the past three years, sending its valuation into orbit. The data analytics and AI company is predicting that its high double-digit growth will continue into next year. One analyst believes Palantir is in a class by itself. 10 stocks we like better than Palantir Technologies › Palantir (NASDAQ: PLTR) has been on fire over the past years, but volatili...
Key Points Palantir stock has gained 1,720% over the past three years, sending its valuation into orbit. The data analytics and AI company is predicting that its high double-digit growth will continue into next year. One analyst believes Palantir is in a class by itself. 10 stocks we like better than Palantir Technologies › Palantir (NASDAQ: PLTR) has been on fire over the past years, but volatility has been prevalent. The data analytics and artificial intelligence (AI) specialist has generated stock price gains of 1,730% over the past three years, but has fallen by at least 20% at least 10 times. There's more. During the two years between early 2021 and early 2023, Palantir stock plummeted more than 80% -- so it isn't for the squeamish. The stock currently trades for an eye-popping 241 times earnings and 115 times forward earnings (as of this writing), yet one Wall Street analyst calls Palantir "extraordinary." Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Citi says Palantir stock is a buy Citi analyst Tyler Radke recently made a splash, maintaining a buy rating and raising his price target on Palantir stock to a Street-high $260. For those keeping score at home, this represents potential gains for investors of 70% compared to Thursday's closing price. The analyst cites Palantir's strong results and relentless growth as the basis for his bullish stance. Radke points out that "These revisions mark some of the strongest at scale we've seen in enterprise software." He goes on to say that "Palantir's momentum increasingly stands out in a software market where accelerating growth stories are rare." I think the analyst hit the nail on the head. In the fourth quarter, Palantir's revenue grew 70% year over year, but this belies the underlying strength of the business. The U.S. commercial segment -- whi...
China’s 15th five-year plan lays out a comprehensive set of quantitative socio-economic development targets, ranging from innovation to food and energy security. To navigate external volatility and sluggish domestic demand, Beijing has built in flexibility by allowing specific economic and innovation metrics to be determined on certain conditions.
China’s 15th five-year plan lays out a comprehensive set of quantitative socio-economic development targets, ranging from innovation to food and energy security. To navigate external volatility and sluggish domestic demand, Beijing has built in flexibility by allowing specific economic and innovation metrics to be determined on certain conditions.
Hugo Kurk/iStock via Getty Images Investment action I had a buy rating for Primoris Services Corporation ( PRIM ) previously, as I saw no fundamental weaknesses in the company. Demand remained strong, and hence, I thought the sell-off was a buying opportunity. I am maintaining a buy rating. Backlog has recovered to >$11.9 billion, Q4 bookings were strong, and the growth setup has gotten better wit...
Hugo Kurk/iStock via Getty Images Investment action I had a buy rating for Primoris Services Corporation ( PRIM ) previously, as I saw no fundamental weaknesses in the company. Demand remained strong, and hence, I thought the sell-off was a buying opportunity. I am maintaining a buy rating. Backlog has recovered to >$11.9 billion, Q4 bookings were strong, and the growth setup has gotten better with gas generation and pipeline both improving. Earnings review PRIM grew Q4 2025 revenue by 6.7% y/y, reaching ~$1.86 billion, with Utilities revenue coming in at ~$698 million and Energy at ~$1.19 billion. The former delivered $73.5 million of gross profit and $43.7 million of EBIT, while the latter delivered $101.5 million of gross profit and $61 million of EBIT. That said, the part that “disappointed” the market, I believe, is that margins moved down y/y. Utilities gross margin was 10.5% (down from 12.1%), while Energy gross margin was 8.5%. Overall gross profit fell by $9.6 million y/y. That led to total EBIT coming in at $77.5 million (down $10.1 million y/y), and the operating margin was 4.2% (it was 5% a year ago). As a result, adj. net income was $59.3 million, down from $61.8 million. The growth story remains solid The demand profile looks much better after this Q4 quarter. It appears I was right that the backlog dropping to $11.1 billion previously was due to timing, not a demand issue. Management said the total backlog ended at more than $11.9 billion and that they booked ~$3 billion of new work in Q4. They also said total MSA (master service agreement) backlog was up >20% y/y. I think these numbers should be strong enough to convince any doubters that demand did not turn weak. Backlog is just one piece of the puzzle. There are multiple other angles that are supporting the bull case. For instance, gas generation is getting bigger. In FY2025, natural gas generation contributed $480 million of revenue, but in 1H 2026, management said they are actively engaged in or ...
(RTTNews) - Medios AG (ILM1.DE, MEDOF), a German specialty pharmaceutical company, on Friday said Chief Financial Officer Falk Neukirch will step down when his current term expires on April 30 at his own request. The company said the decision comes after the repositioning and international expansion of the company and will allow it to realign its leadership structure under Chief Executive Officer ...
(RTTNews) - Medios AG (ILM1.DE, MEDOF), a German specialty pharmaceutical company, on Friday said Chief Financial Officer Falk Neukirch will step down when his current term expires on April 30 at his own request. The company said the decision comes after the repositioning and international expansion of the company and will allow it to realign its leadership structure under Chief Executive Officer Thomas Meier. Neukirch has served as CFO since October 2021, with his term extended in May 2023 through April 2026. Neukirch will remain available to the company in an advisory capacity during the transition period. On Thursday, Medios AG closed trading at EUR 16.02, 0.99% lesser on the XETRA. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Insight with Haslinda Amin, a daily news program featuring in-depth, high-profile interviews and analysis to give viewers the complete picture on the stories that matter. The show features prominent leaders spanning the worlds of business, finance, politics and culture. (Source: Bloomberg)
Insight with Haslinda Amin, a daily news program featuring in-depth, high-profile interviews and analysis to give viewers the complete picture on the stories that matter. The show features prominent leaders spanning the worlds of business, finance, politics and culture. (Source: Bloomberg)
Explosions could be heard outside of the Dubai hotel. With the United Arab Emirates coming under attack by Iranian missiles, the players who were there for an ATP Challenger tournament in nearby Fujairah did not expect to take to the court. To their surprise, they were told it was safe to play in the port city about an hour's drive east of Dubai, home to a key global oil storage and bunkering hub....
Explosions could be heard outside of the Dubai hotel. With the United Arab Emirates coming under attack by Iranian missiles, the players who were there for an ATP Challenger tournament in nearby Fujairah did not expect to take to the court. To their surprise, they were told it was safe to play in the port city about an hour's drive east of Dubai, home to a key global oil storage and bunkering hub. "We expected to stay in shelter because that's what the governments were advising," Australian player James McCabe, who was practising on court when he heard explosions and fighter jets overhead, told BBC Sport. The UAE has come under attack after US-Israeli strikes on Iran, which began last Saturday, prompted retaliatory strikes across the region. The ATP decided on Monday to proceed as planned with the tournament after holding discussions with the local government about its viability. On Tuesday, players ran from the courts when a nearby oil terminal was set ablaze by debris from a drone attack. The rest of the tournament was eventually cancelled, along with a second tournament at the same venue next week, leading to worried players desperately asking for support and scrambling for flights. Two players - Russia's Marat Sharipov and Uzbekistan's Sergey Fomin - remain stranded in the UAE, along with their coaches. Everyone else has found a way to leave. "I don't understand how it was decided the tournament was safe to go to in the first place," said McCabe, now back home in Sydney.
A little known publicly traded company in Nigeria said its revival plan has stalled because it can’t trace its biggest shareholder. Union Dicon Salt Plc has searched for Aims Ltd., which owns 40% of the company, for about 22 years. The maker of edible salts renewed its efforts to find the missing shareholder by issuing a regulatory filing this week asking the investor to get in touch. Shares of Un...
A little known publicly traded company in Nigeria said its revival plan has stalled because it can’t trace its biggest shareholder. Union Dicon Salt Plc has searched for Aims Ltd., which owns 40% of the company, for about 22 years. The maker of edible salts renewed its efforts to find the missing shareholder by issuing a regulatory filing this week asking the investor to get in touch. Shares of Union Dicon have more than doubled this year probably on speculation about the firm’s plan to revive operations and expand, according to Alfred James, its company secretary. But without its top investor — an overseas company — getting regulatory approvals can be a challenge, James said. The company plans to host a board meeting later this year “to put something before shareholders on restructuring,” James said. “If they are available, it will help deal with these issues.” Union Dicon, which lost contact with Aims around 2004, is loss-making and hasn’t paid a dividend in years. The company now relies on rental income and has negative equity after accumulating losses over an extended period, according to its latest financial statements. The Next Africa newsletter runs every weekday. Sign up here for the newsletter, and subscribe to the Next Africa podcast on Apple , Spotify or anywhere you listen .
China has approved a new obesity drug from Pfizer ( PFE ), intensifying competition in a market that is expected to grow even more crowded with upcoming generic versions. The drug, ecnoglutide, is approved for chronic weight management in overweight or obese adults, Pfizer ( PFE ) announced on Friday via WeChat, according to reports. The company secured China rights to the therapy from local start...
China has approved a new obesity drug from Pfizer ( PFE ), intensifying competition in a market that is expected to grow even more crowded with upcoming generic versions. The drug, ecnoglutide, is approved for chronic weight management in overweight or obese adults, Pfizer ( PFE ) announced on Friday via WeChat, according to reports. The company secured China rights to the therapy from local startup Hangzhou Sciwind Bioscience in a $495 million deal in late February. Ecnoglutide is also approved in China as a treatment for Type II diabetes. The injection belongs to the class of GLP-1 receptor agonist drugs sold locally by drugmakers such as Novo Nordisk ( NVO ), Eli Lilly ( LLY ), and Innovent Biologics ( IVBIY ). More on Pfizer Pfizer: Obesity Hype And Vaccine Policy Shocks Pfizer's Portfolio Renewal In Progress - High Yields For The Patient Pfizer's Quiet Cash Comeback Pfizer-backed Priovant wins FDA priority review for lead asset FDA reportedly eyeing staff bonuses to accelerate drug reviews